Search

This reference book compiles the recent advances in computational and experimental modelling to screen and manage Alzheimer's disease. It covers basic etiopathology and various in vitro and in vivo strategies of disease intervention. The book discusses how computer-aided drug design approaches reduce costs and increase biological test efficiency. It reviews the screening for anti-Alzheimer drugs and biomarker analysis of disease inhibitors. The book also explores mechanistic aspects of neurodegeneration and the use of natural products as therapeutics for Alzheimer's disease.Key features: Elaborates on the computational modelling of protein target inhibitors as anti-Alzheimer's agents Explains the role of phytomolecules and natural products in Alzheimer's therapy Reviews preclinical ways to assess drugs focusing on Alzheimer's disease Covers biomarker analysis for Alzheimer's disease Discusses the onset and progression of Alzheimer's disease The book is meant for professionals, researchers, and students of neuroscience, psychology, and computational neurosciences.

This book talks about the multidimensional biological etiology of Alzheimer's disease and autism spectrum disorder which leads to distinctive ways of perception, thinking and learning in affected individuals. It provides a deeper emphasis on the need for early diagnosis, continuous assessment of patients and the proper educational methods and environment required towards enabling people affected with these disorders capable of evolving and learning.This book explores alternative solutions for autism spectrum disorder based on the theory of brain plasticity, the relationship between the gut microbiota and the central nervous system along with genetic factors and toxic metal exposures which are responsible for the oxidative damage resulting in a decreased ability of the patients to use objects or response to auditory stimuli. It also identifies and provides the latest research towards dealing with memory loss, which is the first sign of cognitive impairment followed by behavioral disturbances. These symptoms are associated with a rigorous neuronal decline and the appearance of two brain lesions, senile plaques and neurofibrillary tangles, which are mainly composed of Aβ and hyper phosphorylated tau protein respectively. This book also provides the latest research towards reducing autism disorder severity such as targeting the disease with symptomatic treatments such as cholinesterase inhibitors, NMDA receptor antagonist, β-secretase and γ-secretase inhibitors, α-secretase stimulators, tau inhibitors, immunotherapy, nutraceuticals, and nano drugs.This book will not only be a good resource for professors and lecturers teaching in the area of neuroscience, medicine, biochemistry, neuroinformatics, and nanotechnology, etc. but also for professionals working in the field of occupational therapy and geriatric clinics and rehabilitation.

Environmental Causes and Prevention Measures for Alzheimer's Disease examines the increased incidence of the disease in developed countries and aims to educate neuroscientists, medical practitioners and other educated individuals on new insights into environmental causation, primarily metals. This book looks into the web of evidence around the hypothesis of copper toxicity and the additional role that a high fat diet plays in disease progression and cognition loss. The data and its implications are discussed, along with potential prevention measures. This book will generate excitement and interest among neuroscientists, medical practitioners and other biomedical researchers. - Emphasizes the history and epidemiology of Alzheimer's disease, highlighting its epidemic proportions in developed countries - Discusses data on new environmental factors in developed countries - Provides prevention measures to potentially reduce Alzheimer's rates through diet

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors

The End of Alzheimer's: The Brain and Beyond, Second Edition is the first comprehensive overview on the molecular basis of Alzheimer's outside of the brain, merging the most recent findings within the field into a single book. It aims to educate the reader on the many overlooked aspects of Alzheimer's disease that occur outside the brain. This book uniquely provides step-by-step, peer-reviewed evidence that the current research model may be misguided and that a new and emerging model is more accurate. It carefully outlines the molecular research in Alzheimer's outside the brain and argues that a more thorough, whole-body diagnosis will provide better answers about its causes and lead to new treatments. It is beneficial to researchers who need to be apprised of the emerging science on the causes of Alzheimer's, and will hopefully redirect many into new avenues of cellular research and discovery. - Comprehensive literature-based summary of the current state of molecular Alzheimer's disease research - Details the shortcomings of the prevailing model and therapeutics in development - Reviews blood-based biomarkers for Alzheimer's and their link to amyloid- and Tau-independent causes outside the brain - Describes the tissues outside the brain impacted by Alzheimer's and the underlying molecular causes - Explains the whole-body risks associated with Alzheimer's, along with concomitant measures to slow or prevent the disease - Provides a protocol to properly research, evaluate, measure, diagnose, and potentially treat Alzheimer's patients

This is the first book on the market that explores the importance of curcumin for the treatment of neurological disorders. It has been estimated that 35.6 million people globally had dementia in 2010 and the prevalence of dementia has been predicted to double every 20 years. Thus, 115.4 million people may be living with dementia in 2050. Alzheimer's disease (AD) is the leading cause of dementia and is present in 60%–70% of people with dementia. Unless new discoveries are made in the prevention or treatment of AD, the number of cases in the US alone is estimated to increase threefold, to 13.2 million by the year 2050. Thus, it is important to focus on delaying and treating the onset of AD by curcumin may be an important step for controlling AD. Regular consumption of healthy diet containing curcumin enriched foods, moderate exercise, and regular sleep may produce beneficial effects not only on motor and cognitive functions, but also on memory deficits that occur to some extent during normal aging and to a large extent in AD. Delaying the onset and progression of AD and improving its symptoms by few years with regular consumption of curcumin may relieve some of the burden on health care systems. In service of this goal, this volume gives readers a comprehensive and cutting edge description of the importance of curcumin for the treatment of AD in cell culture and animal models in a manner that is useful not only to students and teachers but also to researchers, dietitians, nutritionists and physicians. It can be used as supplement text for a range of neuroscience and nutrition courses. Clinicians, neuroscientists, neurologists and pharmacologists will find this book useful for understanding molecular aspects of AD treatment by curcumin.

This Pocket Reference offer a multifaceted guide on various aspects of Alzheimer's disease. This thorough review discusses the challenges of diagnosis, different stages of the disease, testing, and current treatment methods, including pharmacological and nonpharmacological management of cognitive decline and symptoms due to Alzheimer's disease. The book also has specific chapters on care issues for patients with Alzheimer's disease, which describes what clinician's and caregivers should expect and how to manage the disease at its various stages. Additionally, the book provides helpful guides, tables, and tips for clinicians and caregivers to help care for the patient and the caregiver themselves.

As indicated by its title, this monograph deals chiefly with morphologically recognizable deviations from the normal anatomical condition of the human CNS. The AD-associated pathology is illustrated from its beginnings (sometimes even in childhood) to its final form, which is reached late in life. The AD process commences much earlier than the clinically recognizable phase of the disorder, and its timeline includes an extended preclinical phase. The further the pendulum swings away from the symptomatic final stages towards the early pathology, the more obvious the lesions become, although from a standpoint of severity they are more unremarkable and thus frequently overlooked during routine neuropathological assessment. For this reason, the authors deal with the hallmark lesions in the early phases of the AD process in considerable detail

A fundamental change is occurring in the understanding of the major neurodegenerative disorders. Protein aggregation is a common emerging theme in diseases as diverse as Alzheimer's, Creutzfeld-Jakob, Parkinson's, and amyotrophic lateral sclerosis. If valid, then a small number of diagnostic and rational therapeutic strategies will emerge over the next few years, based on the common theme of modulation of the production, turnover and deposition of these aggregating proteins. The book provides insights into the cellular and animal models of these diseases, and how the molecular basis of neurodegeneration has become the preferred target of therapy.

There is now considerable genetic evidence that the type 4 allele of the apolipoprotein E gene is a major susceptibility factor associated with late-onset Alzheimer's disease, the common form of the disease defined as starting after sixty years of age. The role of apolipoprotein E in normal brain metabolism and in the pathogenesis of Alzheimer's disease are new and exciting avenues of research. This book, written by the most outstanding scientists in this new filed, is the first presentation of results concerning the implications of apolipoprotein E on the genetics, cell biology, neuropathology, biochemistry, and therapeutic management of Alzheimer's disease.

The fundamental relationship between the neuropathological lesions of Alzheimer's disease and the problem of what underlies the clinical syndrome has remained unsolved since the beginning of the century. Are neurofibrillary tangles and senile plaques directly related to clinical symptoms, or are they epiphenomena that signal synaptic and neuronal loss? In the last decade, these questions have been revisited through systematic studies of individuals with various degrees of dementia using newer immunohistochemical techniques and quantitative approaches to neuropathological study. It is now possible to have a uniform picture of Alzheimer's disease dementia as resulting from collapse of specific neural systems, as pathological changes selectively and specifically involve structures related to memory and higher cognitive functions.This book contains the proceedings of a meeting organized by the Fondation Ipsen which brought together researchers in neuropathology, molecular biology, genetics, neuropsychology, brain imagery and clinical neurology..

Neurons share more similarities with insulin-producing pancreatic islet cells than with any other cell type. The root of this similarity may lie in the islet's evolution from an ancestral insulin-producing neuron. The islet-neuron connection becomes less surprising as we learn more about insulin's involvement in functions far from its traditional role in mediating glucose uptake in muscle. The importance of insulin in the regulation of corporal aging has been established by the dramatic increases in longevity experienced by animals in which the adipose insulin receptor has been genetically eliminated, or in which the insulin-related daf genes have been mutated. New research suggests that, analogous to its influence on corporal aging, insulin also makes important contributions to brain aging and the expression of late-life neurodegenerative disease. Insulin plays a key role in cognition and other aspects of normal brain function. Insulin resistance induces chronic peripheral insulin elevations and is associated with reduced insulin activity both in periphery and brain. The insulin resistance syndrome underlies conditions such as Type 2 diabetes mellitus and hypertension, which are associated with age-related cognitive impairment and Alzheimer's disease. This book discusses the mechanisms through which insulin dysregulation contributes to the development of cognitive impairment and late-life neurodegenerative disease. Given the recent pandemic of conditions associated with insulin resistance, it is imperative that we achieve a comprehensive knowledge of the mechanisms through which insulin resistance affects brain function in order to develop therapeutic strategies to address these effects.

Almost four decades of innovative and intensive research on Alzheimer's disease (AD) have brought major advances in our understanding of its pathogenesis, improved tools for diagnosis, and strategies for its treatment. This research has helped build a solid foundation of knowledge in the neurosciences and biological basis of AD and AD-related neurological disorders. Scientific background and insightful hypotheses are of major relevance in order to approach to an effective therapy for this devastating disease. Current Hypotheses and Research Milestones in Alzheimer's Disease contains 20 seminal chapters by authors with varying views on the neuroanatomical, neuropathological, neuropsychological, neurological, and molecular aspects of AD. These chapters grew out of “Current Hypothesis on Alzheimer's Disease”, held in Viña del Mar, Chile, in November of 2007. Participants included the world's leading Alzheimer's researchers, whose work has illuminated AD investigations during the past few decades. Students, academics and medical professionals will find this text an invaluable addition to the study of this important subject.

Proceedings of the 7th International Conference on Alzheimer's Disease and Parkinson's Disease (ADPD), held March 9-13, 2005 in Sorrento, Italy. The subject matter of the ADPD conferences is unique in that it deals not only with issues related individually to Alzheimer's disease and Parkinson's disease, but also with the integration of these and other related diseases. The most up-to-date techniques and research findings are illustrated in this volume, covering topics such as immunology, neuroscience, pharmacology, genetics, molecular biology, biochemistry and the history, epidemiology, clinical phenomenology, diagnosis, imaging, treatment,and future perspectives of Alzheimer's and Parkinson's Diseases.

In recent years a growing number of proteases have been identified that catalyse peptide bond hydrolysis in the plane of the cellular membrane. These so-called ‘intramembrane-cleaving proteases'(I-CLiPs) are involved in a diverse range of cellular processes, including cell regulation, signalling, quorum sensing, protein processing, lipid metabolism and the unfolded protein response. Some I-CLiPs play critical roles in diseases such as Alzheimer's and viral infection. The authors, who are all world leaders in this exciting field of cell biology, provide an overview of the various proteases including recent data derived from the structural determination of some of the I-CliPs, and discuss the various roles that these proteases play in biology and disease. The aim of this book is to provide an update on this emerging group of unusual but important proteases for both the specialist and those with a broader interest in proteases. Amongst the target audience will be protease researchers, enzymologists, those working in academia and the pharmaceutical industry on biological processes and diseases involving I-CLiPs.

Recent advances in genetics and brain biochemistry point to the Abeta peptide as the major culprit in causing neurodegeneration in Alzheimer's Disease (AD). Abeta Peptide and Alzheimer's Disease is specifically targeted at summarizing current knowledge of the Abeta peptide and its role in AD. Written by leaders in the industrial and academic world specializing in this rapidly moving area, the book covers fundamental biochemical studies on this peptide, the genetic impact on Abeta expression and processing, and various AD therapeutic strategies that target Abeta. Although specifically focusing on the Abeta peptide and AD, there is also some discussion on the similarity and differences of this peptide and AD with other amyloidogenic diseases, such as prion disease, Parkinsons and Huntingtons. This book will primarily be of interest to AD researchers and clinicians but also to researchers of other amyloid diseases.

Few medical or scientific addresses have so unmistakeably made history as the presentation delivered by Alois Alzheimer on November 4, 1906 in Tübingen. The celebratory event,'Alzheimer 100 Years and Beyond'organized on the initiation of the Alzheimer community in Germany and worldwide, in collaboration with the Fondation Ipsen, was the highlight of the Year of Alzheimer. However, beyond these few months of tributes, the centennial offers a unique opportunity to assess both the progress achieved and the uncertainties remaining. This volume, a collection comprised mainly of articles by the invited speakers and also of a few other prominent researchers, is meant to be a record of those events.

Oxidative Stress and Age-Related Neurodegeneration brings together researchers from a variety of fields to compare normal aging and disease-related neurodegeneration in terms of susceptibility to and effects of oxidative stress. They address how these effects can be attenuated, and examine whether antioxidants and natural micronutrients, such as those found in Gingko biloba, green tea, blueberries, and grape seed extract, can play a role. The book includes various ways research is getting to the core of neurodegenerative disease, including the use of proteomics, comparisons to related diseases, and examinations at the cellular and molecular levels.

Brain Repair, addresses all relevant issues underlying the mechanisms of brain damage, brain plasticity and post-traumatic reorganisation after CNS lesions. This book is divided the three major sections that follow; cellular and molecular basis of brain repair, plasticity and reorganisation of neural networks, and experimental therapy strategies. Brain Repair is written by high profile, international experts who describe in detail the newest results from basic research and highlight new model systems, techniques and therapy approaches. Based on a careful analysis of the cellular and molecular reaction patterns of the CNS to lesions, the contributions cover possibilities for endogenous reorganisation and repair as well as exciting new therapies emerging from basic research, some of which have already been introduced into the clinics. Thus, this book is unique in bridging the gap between basic and clinical research. It will be a valuable tool for all students, researchers and clinicians interested in understanding the brain's capacity to cope with lesions and interested in learning about emerging new therapy concepts.

To understand Alzheimer's disease (AD) is one of the major thrusts of present-day clinical research, strongly supported by more fimdamental cellular, biochemical, immunological and structural studies. It is these latter that receive attention within this book. This compilation of 20 chapters indicates the diversity of work currently in progress and summarizes the current state of knowledge. Experienced authors who are scientifically active in their fields of study have been selected as contributors to this book, in an attempt to present a reasonably complete survey of the field. Inevitably, some exciting topics for one reason or another have not been included, for which we can only apologize. Standardization of terminology is often a problem in science, not least in the Alzheimer field; editorial effort has been made to achieve standardization between the Chapters, but some minor yet acceptable personal / author variation is still present, i. e. P-amyloid/amyloid-P; Ap42/Apl-42/APi. 42! The book commences with a broad survey of the contribution that the range of available microscopical techniques has made to the study of Alzheimer's amyloid plaques and amyloid fibrillogenesis. This chapter also serves as an Introduction to the book, since several of the topics introduced here are expanded upon in later chapters. Also, it is significant to the presence of this chapter that the initial discovery of brain plaques, by Alois Alzheimer, utilized light microscopy, a technique that continues to be extremely valuable in present-day AD research.

Providing a cutting-edge profile of research progress in this important field of study, Cholinergic Mechanisms: Function and Dysfunction contains a compilation of the proceedings of the Eleventh ISCM, held in St. Moritz, May 2002. Bringing together 250 contributors from 30 countries, the book presents a comprehensive picture of the cholinergic field. It provides a survey of current understanding of molecular, pharmacological, toxicological, behavioral, and clinical aspects of the cholinergic system. This volume offers a state-of-the-art account of progress in the field from the molecule in the test tube through the cell and the synapse, to the organism and the patient.

1h The 5 International Conference on the Progress in Alzheimer's Disease and Parkinson's 51 1 Disease took place from March 31 to April 5 \ 2001 in Kroto, Japan. This international 1 conference was organized as a joint Congress with the 9 International Catecholamine Symposium. A total of 1258 clinicians and researchers participated in this joint congress 1h from 38 countries in the world. This book represents the proceedings of the 5 Conference on Alzheimer's and Parkinson's disease. The International Conference on the Progress in Alzheimer's and Parkinson's disease was first launched by Professor Abraham Fisher of Israel and Professor Israel Hanin of USA. The first conference was held in Eilat, Israel in 1985. The second conference was organized in Kyoto, Japan in 1989; the third one in Chicago, USA, in 1993, and the fourth one in Eilat, Israel in 1997. The International Catecholamine Symposium (ICS) is an international meeting devoted to the development of basic as well as clinical research on catecholamines. The first Catecholamine Symposium was held in Bethesda, USA in 1958. Since then this symposium has occurred every 5 years. Professor Toshiharu Nagatsu was appointed as 1h the president of the 9 International Catecholamine Symposium, which was to be held in 200 I also in Japan. Therefore, we decided to organize a joint congress of the two meetings, because there is much overlap in research between Alzheimer's disease, Parkinson's disease, and catecholamines. We thank Professor Nagatsu very much for agreeing to organizing this joint congress.

Handbook of the Aging Brain brings together diverse scientific disciplines to cover the most recent research findings in an easy-to-read summary. Scientists and clinicians will find a wide spectrum of subjects including gerontology, neurology, psychology, molecular biology, and cellular biology. The book includes general chapters on the neuroanatomy and neurobiology of the aging brain, and moves on to discussion of specifics including signal transduction, cell death, and specific cellular and neurological changes associated with dementia, Alzheimer's and Parkinson's Disease. Other chapters discuss the affect of aging on learning and memory, language, and cognition.

Volume 42 presents an in-depth review on Alzheimer's Disease as well as a look at several transcription factors. - Clinical features of stroke and the current stasis of stroke therapy - Alzheimers Disease--pathology, pathological proteins, etiology, pathogenesis, neurotransmitter alterations, and treatment strategies - An examination of the regulation of AP-1 and related transcription factors and their role in brain injury and drug abuse-related behavior - Emerging roles of the transcription factor NF(B - Recent advances about the nature of alterations in ion channel structure or function which may be responsible for epileptogenesis - An integrated model accounting for the multiple mechanisms involved in the posttranslational regulation of glutamate ionotroic receptors - Genetic mutation and the Glycine Receptor